Overview

ACTolog in Patients With Solid Cancers

Status:
Active, not recruiting

Trial end date:
2021-09-01

Target enrollment:

Participant gender:

Summary

The study purpose is to learn about the safety and tolerability of IMA101 alone (Cohort 1) or in combination with atezolizumab (Cohort 2) in patients with advanced solid cancers that express pre-defined Immatics tumor targets.

Phase:

Phase 1

Details

Lead Sponsor:

Immatics US Inc.
Immatics US, Inc.

Collaborator:

M.D. Anderson Cancer Center

Treatments:

Aldesleukin
Atezolizumab
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Interleukin-2
Vidarabine